Allogene Therapeutics, Inc. (ALLO) vs Crescent Biopharma, Inc. (CBIO)
A side-by-side comparison of Allogene Therapeutics, Inc. and Crescent Biopharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALLO
Allogene Therapeutics, Inc.
$1.47HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
CBIO
Crescent Biopharma, Inc.
$14.28HealthcareDelayed quote: Oct 6, 2026, 10:10 AM EDT
Total return — ALLO vs CBIO
growth of $100 · dividends reinvested · last 8yALLO -94.0% (-29.6%/yr)CBIO -96.3% (-33.7%/yr)ALLO compounded faster over this window
ALLO CBIO
ALLO vs CBIO: by the numbers
- •CBIO is the larger company ($530M vs $507M market cap).
- •Both run net losses; CBIO's is the smaller (-1371.51% vs -3566.68% net margin).
- •CBIO grew revenue faster over the past five years (39.89% vs -34.47% CAGR).
Metrics side by side
Valuation
| Metric | ALLO | CBIO |
|---|---|---|
| P/S ratio | 109.35 | 44.64 |
| P/B ratio | 1.16 | 3.33 |
Profitability
| Metric | ALLO | CBIO |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -1407.52% |
| Net margin | -3566.68% | -1371.51% |
| ROE | -37.94% | -99.83% |
| ROIC | -34.79% | -102.59% |
Growth (annualized)
| Metric | ALLO | CBIO |
|---|---|---|
| Revenue CAGR (5Y) | -34.47% | 39.89% |
| Total return CAGR (5Y) | -42.72% | -24.40% |
Frequently asked
- Which has grown faster, ALLO or CBIO?
- Over the past five years, CBIO grew revenue faster — ALLO at a -34.47% CAGR versus CBIO at 39.89%.
- How have ALLO and CBIO total returns compared?
- Over the past 5 years, ALLO delivered -42.72% and CBIO delivered -24.40% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Allogene Therapeutics ROECrescent Biopharma ROEAllogene Therapeutics operating marginCrescent Biopharma operating marginAllogene Therapeutics revenue growthCrescent Biopharma revenue growthAllogene Therapeutics free cash flowCrescent Biopharma free cash flow
Allogene Therapeutics & Crescent Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.